CRUN

Publications

" Our main objective is to develop and maintain over time a good expertise and infrastructure ensuring high quality training and clinical research."
Prof Halidou TINTO, PharmD, Msc, PhD Head of the CRUN

Show all

2021

Mehreen S Datoo; Magloire H Natama; Athanase Somé; Ousmane Traoré; Toussaint Rouamba; Duncan Bellamy; Prisca Yameogo; Daniel Valia; Moubarak Tegneri; Florence Ouedraogo; Rachidatou Soma; Seydou Sawadogo; Faizatou Sorgho; Karim Derra; Eli Rouamba; Benedict Orindi; Fernando Ramos Lopez; Amy Flaxman; Federica Cappuccini; Reshma Kailath; Sean Elias; Ekta Mukhopadhyay; Andres Noe; Matthew Cairns; Alison Lawrie; Rachel Roberts; Innocent Valéa; Hermann Sorgho; Nicola Williams; Gregory Glenn; Louis Fries; Jenny Reimer; Katie J Ewer; Umesh Shaligram; Adrian V S Hill; Halidou Tinto

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial (Journal Article)

In: Lancet, 397 (10287), pp. 1809–1818, 2021, ISSN: 1474-547X 0140-6736, (Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. PMID: 33964223 PMCID: PMC8121760).

(Abstract | Links | BibTeX | Altmetric | Tags: Adjuvants, Burkina Faso, Double-Blind Method, Falciparum/prevention & control, Female, Hepatitis B Surface Antigens, Humans, Immunogenicity, Immunologic/administration & dosage, Infant, Malaria, Malaria Vaccines/therapeutic use, Malaria/prevention & control, Male, Nanoparticles/administration & dosage, Proportional Hazards Models, Protozoan Proteins/immunology, Saponins/administration & dosage, Treatment Outcome, Vaccine, Vaccines, Virus-Like Particle/therapeutic use)

Efficacy of a low-dose candidate malaria vaccine, R21 in  adjuvant Matrix-M, with seasonal administration to children in  Burkina Faso: a randomised controlled trial